New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor microenvironment interacts with tumor cells, establishing an atmosphere to contribute or suppress the tumor development. Among the cells which play a role in the tumor microenvironment, mesenchymal stem cells (MSCs) have been demonstrated to possess the ability to orchestrate the fate of tumor cells, drawing the attention to the field. MSCs have been considered as cells with double-bladed effects, implicating either tumorigenic or anti-tumor activity. On the other side, the promising potential of MSCs in treating human cancer cells has been observed from the clinical studies. Among the beneficial characteristics of MSCs is the natural tumor-trophic migration ability, providing facility for drug delivery and, therefore, targeted treatment to detach tumor and metastatic cells. Moreover, these cells have been the target of engineering approaches, due to their easily implemented traits, in order to obtain the desired expression of anti-angiogenic, anti-proliferative, and pro-apoptotic properties, according to the tumor type. Tumor angiogenesis is the key characteristic of tumor progression and metastasis. Manipulation of angiogenesis has become an attractive approach for cancer therapy since the introduction of the first angiogenesis inhibitor, namely bevacizumab, for metastatic colorectal cancer therapy. This review tries to conclude the approaches, with focus on anti-angiogenesis approach, in implementing the MSCs to combat against tumor cell progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Dasari, V. R., Kaur, K., Velpula, K. K., Gujrati, M., Fassett, D., Klopfenstein, J. D., Dinh, D. H., & Rao, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010350 · Cited by 151 · cited 1×
“Additionally, treatment of glioma cells with umbilical cord blood-derived stem cells caused inhibition of focal adhesion kinase (FAK)-mediated angiogenesis (92), upregulation of phosphatase and tensin homolog (PTEN) expression in glioma cells, and down-modulation of Akt and PI3K signaling pathway molecules in the nude…”
BackgroundRetractedDasari, V. R., Velpula, K. K., Kaur, K., Fassett, D., Klopfenstein, J. D., Dinh, D. H., Gujrati, M., & Rao, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011813 · Cited by 87 · cited 1×
“Alternately, this eventuated in downregulation of XIAP activating caspase-3 and caspase-9 to stimulate apoptosis in glioma cells (94).”
BackgroundRetractedKern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 2×
“The expansion and differentiation capacity as well as the immunophenotype of MSCs obtained from adipose tissue are nearly the same as those extracted from bone marrow (27).”
BackgroundMesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 2×
“Moreover, MSCs from prostate cancer and breast cancer cell lines overexpress CCL5, which in turn up-modulated the expression of genes involved in EMT, such as zinc finger E-box-binding homeobox 1, CXCR4, and Snail (76, 85).”
BackgroundInduction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879 · cited 1×
“It has been identified that tumor-mediated angiogenesis stems from an aberrant regulation of both pro-angiogenic and antiangiogenic agents as well as via growth factors of the tumor microenvironment (6, 179).”
BackgroundVEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 3×
“Three subfamilies of 14 RTK, namely Ang/Tie-2, VEGF/VEGFR2, and Ephrin B2/EphB4 are particularly overexpressed in the endothelial cells.”
BackgroundVEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 1×
“The vessel normalization was attributed to reduced vessel diameter and permeability (182, 183) as well as the increased mural cell coverage of the small vasculature (184).”
BackgroundImmunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 1×
“Additionally, MSCs were observed to suppress immune responses, leading to tumor development (79).”
BackgroundHuman mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells
Spaeth, E., Klopp, A., Dembinski, J., Andreeff, M., & Marini, F. (2008) · Gene Therapy · doi:10.1038/gt.2008.39 · Cited by 579 · cited 1×
“Several inflammatory mediators that are produced by wounds are found in the tumor microenvironment and are believed to be involved in attracting MSCs to these sites (41).”
BackgroundAdipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431 · cited 1×
“Bone marrow-derived MSCs obtained from other tissues, like adipose tissue, can also be potentially utilized as anticancer gene vehicles for cancer treatment (18, 19).”
BackgroundMesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417 · cited 1×
“Studies have indicated the therapeutic effects of engineered MSCs to express TRAIL in both cell lines or animal models of tumors, such as gliomas (118–120), colorectal carcinoma (121), and lung, breast, squamous, and cervical cancers (122).”
BackgroundRamasamy, R., Lam, E. W.-F., Soeiro, I., Tisato, V, Bonnet, D., & Dazzi, F. (2007) · Leukemia · doi:10.1038/sj.leu.2404489 · Cited by 404
McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45273 · Cited by 380 · cited 2×
“As well, T-MSCs obtained from ovarian cancer increased the proliferation of tumor cells (86).”
BackgroundHong, H. S., Lee, J., Lee, E., Kwon, Y. S., Lee, E., Ahn, W., Jiang, M. H., Kim, J. C., & Son, Y. (2009) · Nature Medicine · doi:10.1038/nm.1909 · Cited by 349
Qiao, L., Xu, Z.-L., Zhao, T.-J., Ye, L.-H., & Zhang, X.-D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.032 · Cited by 313
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
The roles of mesenchymal stem cells in tumor inflammatory microenvironment
Sun, Z., Wang, S., & Zhao, R. C. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-14 · Cited by 249 · cited 1×
“The other type of MSCs, the tumor-derived MSCs (T-MSCs), demonstrate phenotype similarity with naïve MSCs but exhibit stronger immunosuppressive activity and proliferative capacity than naïve MSCs (80).”
BackgroundMesenchymal Stromal Cells Promote Tumor Growth through the Enhancement of Neovascularization
Suzuki, K., Sun, R., Origuchi, M., Kanehira, M., Takahata, T., Itoh, J., Umezawa, A., Kijima, H., Fukuda, S., & Saijo, Y. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00157 · Cited by 244 · cited 1×
“Nonetheless, adverse roles of naïve MSCs have also been reported, as these cells were related to enhanced tumor angiogenesis in colon cancer cell lines (69, 70), MSC differentiation to vascular endothelial cells in melanoma (71), and promotion of cancer stem cells (CSCs) that enhance tumorigenesis, metastasis and recu…”
BackgroundThe growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo
Lu, Y.-R., Yuan, Y., Wang, X.-J., Wei, L.-L., Chen, Y.-N., Cong, C., Li, S.-F., Long, D., Tan, W.-D., Mao, Y.-Q., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.2.5296 · Cited by 225
Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model
Sun, B., Roh, K.-H., Park, J.-R., Lee, S.-R., Park, S.-B., Jung, J.-W., Kang, S.-K., Lee, Y.-S., & Kang, K.-S. (2009) · Cytotherapy · doi:10.1080/14653240902807026 · Cited by 214 · cited 1×
“Moreover, naïve MSCs can also activate apoptosis in tumor cells (65) through upregulation of caspase 3 (61).”
BackgroundXu, W.-T., Bian, Z.-Y., Fan, Q.-M., Li, G., & Tang, T.-T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.022 · Cited by 206
Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., Kan, B., Du, L., Wang, B., Wei, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.3 · Cited by 173
Seo, S. H., Kim, K. S., Park, S. H., Suh, Y. S., Kim, S. J., Jeun, S.-S., & Sung, Y. C. (2011) · Gene Therapy · doi:10.1038/gt.2010.170 · Cited by 148 · cited 1×
“IL-12 expressing MSCs were observed to have antitumor functions in mice with cervical tumors (99) and renal cell carcinomas (100).”
BackgroundDarash-Yahana, M., Gillespie, J. W., Hewitt, S. M., Chen, Y.-Y. K., Maeda, S., Stein, I., Singh, S. P., Bedolla, R. B., Peled, A., Troyer, D. A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006695 · Cited by 143
Razmkhah, M., Jaberipour, M., Erfani, N., Habibagahi, M., Talei, A.-R., & Ghaderi, A. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2010.09.005 · Cited by 116
Stem cells as vectors for antitumour therapy
Loebinger, M. R., & Janes, S. M. (2010) · Thorax · doi:10.1136/thx.2009.128025 · Cited by 109 · cited 1×
“MSCs have been shown to have specific tumor-oriented migration as well as incorporation capacity in several preclinical models, demonstrating the potential for MSCs to be used as favorable carriers for anticancer compounds (17).”
BackgroundHonoki, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1220 · Cited by 90 · cited 1×
“Among the other unwanted influences of naïve MSCs in tumors are enhancement of tumor cell migration mediated by release of chemokines, such as CXCR4 (75), CCL5 (76, 77), vascular cell adhesion molecules (VCAMs), and intercellular adhesion molecules (ICAMs) (78).”
Background
Cited by
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., & Lorenc, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165840 · Cited by 299
Yarahmadi, A., Dorri Giv, M., Hosseininejad, R., Rezaie, A., Mohammadi, N., Afkhami, H., & Farokhi, A. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1472679 · Cited by 21
“One of the ways that has created new hope for the treatment and reducing the complications of GBM is mesenchymal stem cell therapy (232).”
Teymouri, S., Yousefi, M. H., Heidari, S., Farokhi, S., Afkhami, H., & Kashfi, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-024-10163-x · Cited by 11
“MSCs can contribute to neovascularization by releasing pro-angiogenic factors such as hypoxia-inducible factor 1 (HIF-1), VEGF, EGF, and CXCL12 [ 125 ].”
Metadata
- Authors
- Javan, M. R., Khosrojerdi, A., & Moazzeni, S. M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2019-08-28
- Volume
- 9
- Pages
- 840-840
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2968047484
- Cited by
- 67
- References
- 30
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.